Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic ceftriaxone for prevention of early lower respiratory tract infection in mechanically ventilated adults with acute brain injury
ACTRN12623000958684Phase 2Terminated
- Sponsor
- Medical Research Institute of New Zealand
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in pulmonary infection and ventilator-associated pneumonia (VAP) comparing Ceftriaxone prophylaxis with Matched placebo (2 arms). Primary endpoint: Primary outcome: early lower respiratory tract infection requiring antibiotics in ICU. Started Feb 2024; status: terminated.
02
Drugs
ceftriaxone
03
Conditions
pulmonary infectionventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on ACTRN12623000958684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12623000958684.